HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Integrative clinical genomics of advanced prostate cancer.

Abstract
Toward development of a precision medicine framework for metastatic, castration-resistant prostate cancer (mCRPC), we established a multi-institutional clinical sequencing infrastructure to conduct prospective whole-exome and transcriptome sequencing of bone or soft tissue tumor biopsies from a cohort of 150 mCRPC affected individuals. Aberrations of AR, ETS genes, TP53, and PTEN were frequent (40%-60% of cases), with TP53 and AR alterations enriched in mCRPC compared to primary prostate cancer. We identified new genomic alterations in PIK3CA/B, R-spondin, BRAF/RAF1, APC, β-catenin, and ZBTB16/PLZF. Moreover, aberrations of BRCA2, BRCA1, and ATM were observed at substantially higher frequencies (19.3% overall) compared to those in primary prostate cancers. 89% of affected individuals harbored a clinically actionable aberration, including 62.7% with aberrations in AR, 65% in other cancer-related genes, and 8% with actionable pathogenic germline alterations. This cohort study provides clinically actionable information that could impact treatment decisions for these affected individuals.
AuthorsDan Robinson, Eliezer M Van Allen, Yi-Mi Wu, Nikolaus Schultz, Robert J Lonigro, Juan-Miguel Mosquera, Bruce Montgomery, Mary-Ellen Taplin, Colin C Pritchard, Gerhardt Attard, Himisha Beltran, Wassim Abida, Robert K Bradley, Jake Vinson, Xuhong Cao, Pankaj Vats, Lakshmi P Kunju, Maha Hussain, Felix Y Feng, Scott A Tomlins, Kathleen A Cooney, David C Smith, Christine Brennan, Javed Siddiqui, Rohit Mehra, Yu Chen, Dana E Rathkopf, Michael J Morris, Stephen B Solomon, Jeremy C Durack, Victor E Reuter, Anuradha Gopalan, Jianjiong Gao, Massimo Loda, Rosina T Lis, Michaela Bowden, Stephen P Balk, Glenn Gaviola, Carrie Sougnez, Manaswi Gupta, Evan Y Yu, Elahe A Mostaghel, Heather H Cheng, Hyojeong Mulcahy, Lawrence D True, Stephen R Plymate, Heidi Dvinge, Roberta Ferraldeschi, Penny Flohr, Susana Miranda, Zafeiris Zafeiriou, Nina Tunariu, Joaquin Mateo, Raquel Perez-Lopez, Francesca Demichelis, Brian D Robinson, Marc Schiffman, David M Nanus, Scott T Tagawa, Alexandros Sigaras, Kenneth W Eng, Olivier Elemento, Andrea Sboner, Elisabeth I Heath, Howard I Scher, Kenneth J Pienta, Philip Kantoff, Johann S de Bono, Mark A Rubin, Peter S Nelson, Levi A Garraway, Charles L Sawyers, Arul M Chinnaiyan
JournalCell (Cell) Vol. 161 Issue 5 Pg. 1215-1228 (May 21 2015) ISSN: 1097-4172 [Electronic] United States
PMID26000489 (Publication Type: Journal Article, Multicenter Study, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
CopyrightCopyright © 2015 Elsevier Inc. All rights reserved.
Topics
  • Cohort Studies
  • Gene Expression Profiling (methods)
  • Humans
  • Male
  • Mutation
  • Neoplasm Metastasis (drug therapy, genetics, pathology)
  • Prostatic Neoplasms, Castration-Resistant (drug therapy, genetics, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: